Scholar Rock (SRRK) stated SRK-439 · topline data: “in H2 2026” (SEC Exhibit 99.1, filed ); the most recent dated timing wording located () was “in late 2026” (Company press release · and SEC Exhibit 99.1 · ); “in the second half of 2026” (SEC Form 10-Q · ).
On , documents dated the same day used different timing wording: “in late 2026” (Company press release · and SEC Exhibit 99.1 · ); “in the second half of 2026” (SEC Form 10-Q · ). Each source is shown separately; no order within that day is inferred.
When did Scholar Rock say SRK-439 results would come?
On , Scholar Rock wrote in its SEC Form 10-Q: “A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Equivalent half-year, quarter, and year notations are compared together while original wording stays visible. Qualifiers such as early, mid, late, and end remain distinct. A slash and or are compared together for two complete timing alternatives with explicit years. Each source is compared with the preceding checked date. Different wording in documents from the same day is shown separately, without assigning an order within that day. No comparison is made against a preceding date with different timing expressions. Status is set by founder review of the original filings.
Document
Date
Event retained
Exact company wording
Review
Source
SEC Exhibit 99.1
Initial entry within checked sources: “in H2 2026”
SRK-439 Phase 1 trial ongoing in healthy volunteers; topline data expected in H2 2026
: Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged.
A correction is added here with its date, what changed, why, and the evidence. The earlier version is not deleted. Report an error: hello@orionbiotechai.com. If you want your name shown with the correction, include it; otherwise no name is shown.
Program file
Name as filed
SRK-439
Other names in filings
None listed
Indication in the filing
rare, severe, and debilitating neuromuscular diseases
Trials named in the same filing
None listed
Latest timing wording
“A Phase 1 study of SRK-439 in healthy volunteers is currently underway, with topline data anticipated in the second half of 2026.”
Scholar Rock (SRRK) — SRK-439 · topline data: “in H2 2026” (SEC Exhibit 99.1 2026-01-12); statement retained “in the second half of 2026” (2026-03-03); statement retained “in the second half of 2026” (2026-05-07); statement retained “in the second half of 2026” (2026-05-07); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); wording changed from “in the second half of 2026” (2026-05-07) and “in the second half of 2026” (2026-05-07) to “in late 2026” (2026-08-06); statement retained “in the second half of 2026” (2026-08-06). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000110465926056667/srrk-20260331x10q.htm | https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2026-financial-results-and | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm
Terms
First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology. Status definitions.
